-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$109.7112.84% Upside
Recent Analyst Forecasts and Stock Ratings
Blueprint Medicines Corporation Frequently Asked Questions
-
What analysts cover Blueprint Medicines Corporation?
Blueprint Medicines Corporation has been rated by research analysts at Needham, UBS, Stifel Nicolaus, Oppenheimer, Barclays, Leerink Partners in the past 90 days.